- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.09. | Cyclerion cycles through latest pivot, reinventing itself as neuro biotech | 4 | FierceBiotech | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.09. | Cyclerion sichert sich MIT-Lizenz für Programm gegen therapieresistente Depressionen | 1 | Investing.com Deutsch | ||
| 23.09. | Cyclerion signs MIT license for treatment-resistant depression program | 1 | Investing.com | ||
| 23.09. | Cyclerion stock soars after MIT licensing deal to relaunch company | 1 | Investing.com | ||
| 23.09. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09. | Cyclerion Therapeutics, Inc.: Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | 128 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen | |
| 05.08. | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.06. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.12.24 | Pre-market Movers: PainReform, Bluejay Diagnostics, Psyence Biomedical, Cyclerion Therapeutics, Verint Systems | 882 | AFX News | OVERLAND PARK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over 142% at... ► Artikel lesen | |
| 27.11.24 | Pre-market Movers: Primega Group, HWH International, Cyclerion Therapeutics, Interactive Strength, Infobird | 1.131 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green HWH International Inc. (HWH) is up over 69% at $1.04.
Cyclerion... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 104,24 | -3,49 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 20,190 | 0,00 % | Morning Market Movers: Olema Pharmaceuticals, LifeMD, Alpha Technology Group, Intellinetics See Big Swings | HELSINKI (dpa-AFX) - At 8:10 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 13,000 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| DISC MEDICINE | 89,74 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,84 | +0,23 % | TD Cowen reiterates Hold rating on Avidity Biosciences stock at $74 | ||
| TANGO THERAPEUTICS | 8,000 | +0,25 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | - Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months- - Combination studies with RAS(ON) inhibitors ongoing, data anticipated... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 43,460 | -1,81 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ARCUTIS BIOTHERAPEUTICS | 27,280 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,385 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,160 | 0,00 % | Recursion's Incoming CEO Needs To Prove That AI Drug Development Can Pay Off | ||
| UPSTREAM BIO | 25,560 | 0,00 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 34,410 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| INVIVYD | 2,520 | 0,00 % | Invivyd prices $125M stock offering at $2.50 per share | ||
| PRAXIS PRECISION MEDICINES | 184,22 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 9,740 | 0,00 % | VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know |
CYCLERION THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.